Abstract A029: Structure-guided design of SLC1A1/EAAT3-selective inhibitors reveals a metabolic vulnerability in kidney cancer
Year: 2026
Type: conference-abstract
Source: Cancer Research
Institutions: Cleveland Clinic, Weill Cornell Medicine
Language: English
Subfield: Biochemistry
Domain: Life Sciences
Open Access status: closed
OpenAlex ID: W7135238065
Cites:
Cited by:
Related to:
